SCHEMBL30003812

SCHEMBL30003812

CON(C)C(=O)c1ccc(C)nn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.37
NNMT P40261 1/20 0.37
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
TRPM8 Q7Z2W7 2/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
APLNR P35414 1/20 0.32
ICAM1 P05362 1/20 0.32
SELE P16581 1/20 0.32
SLC6A3 Q01959 1/20 0.32
KDM4E B2RXH2 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24724207 1.00 MLYCD (0.37) MLYCDNNMTCLK1DYRK1ADYRK1B
SCHEMBL18667426 0.81 KDM4A (0.38) NNMTMEN1KMT2ARAB9AAPLNR
SCHEMBL2541582 0.81 PKM (0.39) MLYCDNNMTCLK1DYRK1ADYRK1B
SCHEMBL3739445 0.77 P2RX7 (0.49) MLYCDCLK1DYRK1ADYRK1BTRPM8
SCHEMBL31226268 0.77 MAPK1 (0.48) NNMTMEN1KMT2ATDP1PKM
SCHEMBL11886132 0.77 MAPK1 (0.48) NNMTMEN1KMT2ATDP1PKM
SCHEMBL11929579 0.74 TDP1 (0.40) MLYCDDYRK1AMEN1KMT2ATDP1
SCHEMBL27656 0.74 P2RX7 (0.46) MLYCDCLK1DYRK1ADYRK1BTRPM8
SCHEMBL2882770 0.73 KMT2A (0.49) MEN1KMT2ATDP1RAB9AKDM4E
SCHEMBL12143401 0.72 SPR (0.36) RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 US disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 CN disclosed
EP-4347036-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
WO-2022253255-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 MLYCD 213/4885NNMT 583/4885CLK1 4271/4885
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 MLYCD 213/4885NNMT 583/4885CLK1 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.